This is a routine insider sale consistent with a pre-arranged option exercise plan. The amount is immaterial relative to market cap and the insider's prior selling pattern. No trading action warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $29.26entry
- T+1 · 6mo ago 0.00%α −0.54% · $29.26
- T+5 · 6mo ago −9.81%α −9.89% · $26.39
- T+20 · 5mo ago −18.80%α −17.07% · $23.76
- T+60 · 3mo ago −7.76%α −12.14% · $26.99
Price Chart
How similar events traded
Executive Summary
Officer David Rodman filed a Form 144 notice of intent to sell 2,171 shares of Mineralys Therapeutics common stock, valued at approximately $64,500. This is a small, routine sale by an insider who has been selling similar amounts monthly since February 2026, and the filing itself does not indicate a material change in the company's outlook.
Key Facts
- Insider David Rodman (Officer) filed Form 144 to sell 2,171 shares of MLYS common stock.
- Estimated sale value: approximately $64,500.
- The filing date is May 11, 2026.
- Rodman has executed 12 prior sales of similar size since February 2026, totaling roughly $1.9M.
- The shares are to be sold via Merrill Lynch, with the transaction described as a broker-assisted cashless exercise of employee stock options.
- The company's market cap is $2.4B, making this sale de minimis (0.003% of market cap).
Financial Impact
Sale of ~$64,500, representing 0.003% of MLYS's $2.4B market cap.
Risk Factors
- Insider selling pattern could accelerate if company fundamentals deteriorate, but no such signal here.
- Form 144 is an intent to sell; the actual sale may not occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000229 |
| Document: 0001964306-26-000229-index.html | 0001964306-26-000229 |
| Document: 0001964306-26-000229.txt | 0001964306-26-000229 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers